BACE2 Expression Increases in Human Neurodegenerative Disease  by Holler, Christopher J. et al.
The American Journal of Pathology, Vol. 180, No. 1, January 2012
Copyright © 2012 American Society for Investigative Pathology.
Published by Elsevier Inc. All rights reserved.
DOI: 10.1016/j.ajpath.2011.09.034Neurobiology
BACE2 Expression Increases in Human
Neurodegenerative DiseaseChristopher J. Holler,* Robin L. Webb,*
Ashley L. Laux,* Tina L. Beckett,†
Dana M. Niedowicz,*† Rachel R. Ahmed,†
Yinxing Liu,* Christopher R. Simmons,†‡
Amy L. S. Dowling,†§ Angela Spinelli,¶
Moshe Khurgel,¶ Steven Estus,†‡
Elizabeth Head,†§ Louis B. Hersh,* and
M. Paul Murphy*†
From the Departments of Molecular and Cellular Biochemistry,*
Physiology ‡ and Molecular and Biomedical Pharmacology,§ the
Sanders-Brown Center on Aging,† and the UK Center for Muscle
Biology, University of Kentucky, Lexington, Kentucky; and the
Department of Biology,¶ Bridgewater College, Bridgewater,
Virginia
-Secretase, the rate-limiting enzymatic activity in the
production of the amyloid- (A) peptide, is a major
target of Alzheimer’s disease (AD) therapeutics. There
are two forms of the enzyme: -site A precursor
protein cleaving enzyme (BACE) 1 and BACE2. Al-
though BACE1 increases in late-stage AD, little is
known about BACE2. We conducted a detailed exam-
ination of BACE2 in patients with preclinical to
late-stage AD, including amnestic mild cognitive im-
pairment, and age-matched controls, cases of fronto-
temporal dementia, and Down’s syndrome. BACE2 pro-
tein and enzymatic activity increased as early as
preclinical AD and were found in neurons and astro-
cytes. Although the levels of total BACE2 mRNA were
unchanged, the mRNA for BACE2 splice form C (miss-
ing exon 7) increased in parallel with BACE2 protein
and activity. BACE1 and BACE2 were strongly corre-
lated with each other at all levels, suggesting that their
regulatory mechanisms may be largely shared. BACE2
was also elevated in frontotemporal dementia but not
in Down’s syndrome, even in patients with substan-
tial A deposition. Thus, expression of both forms of
-secretase are linked and may play a combined
role in human neurologic disease. A better under-
standing of the normal functions of BACE1 and
BACE2, and how these change in different disease
states, is essential for the future development of ADtherapeutics. (Am J Pathol 2012, 180:337–350; DOI:
10.1016/j.ajpath.2011.09.034)
Alzheimer’s disease (AD) is the most common age-re-
lated neurodegenerative disease. Although progressive
memory loss is the best known clinical symptom, patients
also exhibit a wide range of other behavioral distur-
bances, from paranoia and delusions to a gradual de-
cline in language ability. In the affected brain, two forms
of neuropathology develop in characteristic patterns: ex-
tracellular amyloid deposits, referred to as plaques, and
intracellular neurofibrillary tangles (NFTs). The presence
of all three—NFTs, plaques, and cognitive impairment—
define AD as a clinical entity. The lack of an effective,
disease-modifying therapy for AD is one of the greatest
unmet medical needs facing modern society.
Despite gaps in our knowledge about the general
causes of AD, much is known about the molecular biol-
ogy underlying several key pathways. A large body of
compelling evidence provides broad support for the idea
that the amyloid- (A) peptide is the causative patho-
logic agent in AD. The A peptide is produced from the
larger A precursor protein (APP) through two sequential
enzymatic activities, - and -secretase. -Secretase first
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sAPP. A membrane-bound fragment, C-terminal frag-
ment of APP (CTF) , remains and is, in turn, proteolyti-
cally cleaved by -secretase to generate A and a cyto-
solic fragment, which may offer a clue to the physiologic
function of APP.1 -Secretase is the rate-limiting enzyme
in the production of A, a limitation that likely arises
because it does not often encounter its APP substrate in
the cell.2 Consequently, targeting -secretase is consid-
ered a prime candidate strategy for developing an effec-
tive AD therapy.
The atypical aspartyl protease -site APP cleaving en-
zyme (BACE1) was identified as the major -secretase
enzyme by multiple research groups slightly more than a
decade ago.3 Mature BACE1 is a palmitoylated glyco-
protein that is processed to an active form by removal of
a prodomain by a furin-like convertase activity.4 BACE1 is
involved in nervous system myelination,5 and increases
in BACE1 after traumatic brain injury may reflect this
function.6 The BACE1 cleavage product of APP (sAPP),
may have distinct physiologic functions that distinguish it
from the -secretase product (sAPP).7 There are five
BACE1 splice variants, although it is unknown whether
their variation is related to the development of AD.8
Considerably less is known about the homologous en-
zyme BACE2. BACE1 and BACE2 compete for substrate
and can both cleave APP at the -site.9,10 Although
BACE2 is present in most peripheral tissues,11 there is a
moderate amount of BACE2 expression in the human
brain.12 In the brain, BACE2 is believed to be mostly
astrocytic, whereas BACE1 is largely neuronal.10 BACE2
is located on chromosome 21 in the Down’s syndrome
(DS) obligate region and may contribute to amyloid ab-
normalities in these individuals.13,14
Knockout of BACE1 in the mouse leads to the abolish-
ment of A, sAPP, and CTF production in the brain.15
Crossing BACE1 knockout mice with models of amyloid
deposition leads to reduced brain A and improved cog-
nitive function.16 However, BACE1 knockout animals
have many subtle phenotypic alterations, including defi-
cits in long-term potentiation, increased seizure suscep-
tibility, and schizophrenic behavior.17,18 BACE1 knock-
outs exhibit residual -secretase activity that may be
attributable to BACE2.15,19,20 Our understanding of the
relationship between BACE1 and BACE2, and how they
may be connected in human disease, is incomplete.
Table 1. Subject Demographic Data
Sex, M/F (no.) Age (years)* PMI (ho
Case series I
Control 5/4 84.3  5.1 2.8 
FTD 3/3 61.0  14.6 4.8 
Amnestic MCI 3/4 89.0  5.8 2.8 
Preclinical AD 1/9 85.6  3.7 2.6 
AD 4/6 83.4  5.7 3.1 
Case series II
Control 10/10 37.0  21.8 9.5 
DS 18/10 34.4  21.2 13.5 
Series I measurements were made from the SMTG (areas 21 and 22) an
*Values are given as mean  SD.
F, female; M, male; MMSE, Mini-Mental State Examination; NA, not applicablThe amount of active BACE1 protein is elevated in
the brain in late-stage AD,21–25 and higher levels of
BACE1 are also observed in the cerebrospinal fluid.26
Individuals with mild cognitive impairment (MCI), pre-
sumed to be the earliest detectable clinical phase of AD,
also show elevated BACE1 expression in cerebrospinal
fluid27 and increased -secretase activity from plate-
lets.28 These studies have raised the intriguing possibility
that changes in -secretase activity may be directly con-
nected to the development of AD; however, important
questions remain unanswered. To be causally involved in
AD, the increase in BACE1 should occur in the brain at an
early, preclinical stage. This has not been conclusively
established. Furthermore, minimal information is avail-
able on how specific the changes in BACE1 are to AD
compared with other neurologic diseases.26 Finally, the
function of BACE2 in the brain, and its possible role in
disease, is unresolved. We recently observed unexpect-
edly high levels of active BACE2 protein in the AD
brain,22 raising the question of whether it may have been
overlooked in earlier studies. In this study, we attempted
to answer these questions by conducting a detailed ex-
amination of BACE1 and BACE2 in a broad cohort of
patients.
Materials and Methods
Subjects
We selected two series of cases to study two overlapping
questions (Table 1). The first case series (see Supple-
mental Table S1 at http://ajp.amjpathol.org) was chosen
to examine the role of -secretase in age-related neuro-
degenerative disease. These samples were obtained
from the tissue repository of the Alzheimer’s Disease
Center at the University of Kentucky, Sanders-Brown
Center on Aging. Controls (n  9) were age matched to
disease-affected cases [preclinical AD (PCAD): n  10;
amnestic MCI: n  7; and AD: n  10]. PCAD cases
(often referred to as high-pathology controls) were de-
fined as those that met the National Institute on Aging–
Reagan Institute neuropathology criteria for likely AD but
exhibited no clinical signs of dementia.29 Amnestic MCI
was defined as per the criteria of Petersen et al.30 We
included six cases of frontotemporal dementia (FTD) as
Brain weight (g)* Braak stage (median) MMSE score*
1234  163 I 28.4  1.5
941  169 0 7.8  9.0
1118  132 IV 24.8  3.1
1173  110 IV 29.4  0.7
1074  89 VI 9.9  6.0
NA NA NA
NA NA NA
; series II measurements were made from the middle frontal gyrus (area 9).urs)*
0.8
1.0
0.5
0.5
0.6
5.5
8.5
d the CBe or unavailable; PMI, postmortem interval.
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control.31 A is not considered to play a significant role in
FTD. Details of the recruitment, inclusion criteria, and
mental status test battery for the control group have been
described previously.32 Details of the tissue collection
procedures and consensus diagnosis have also been
described (see Supplemental Figure S1 at http://ajp.
amjpathol.org).33 The second case series (see Supple-
mental Table S2 at http://ajp.amjpathol.org) was selected
to better elucidate the role of A deposition as a feed-
back mechanism for changes in -secretase. Individuals
with DS develop A deposition and other AD-like abnor-
malities with age. DS cases and controls were obtained
from the Alzheimer’s Disease Center of the University of
California at Irvine brain tissue repository and the Na-
tional Institute of Child Health and Human Development
Brain and Tissue Bank for Developmental Disorders (Uni-
versity of Maryland). Control brains had no history of
antemortem dementia. An analysis of RNA integrity num-
bers, controlling for age and postmortem interval, indi-
cated no significant difference in tissue quality between
sites (n  46; F1,42  0.9, P  0.4).
Tissue Collection and Processing
Frozen samples were homogenized using a PowerMax
Advanced Homogenizing System 200 (VWR, Batavia, IL)
in five volumes (wet w/v) of tissue lysis buffer [10 mmol/L
sodium acetate (NaOAc), 3.0 mmol/L NaCl, 0.1% Triton
X-100 (Roche Diagnostics GmbH, Mannheim, Germany),
0.32 mol/L sucrose, pH 5.0]. The buffer was supple-
mented with a complete protease inhibitor cocktail with
EDTA (PIC; Amresco, Solon, OH), with 100 nmol/L pep-
statin A added (Sigma-Aldrich; St. Louis, MO). Whole
tissue homogenate was centrifuged at 2000  g for 15
minutes to pellet insoluble material, followed by an addi-
tional spin at 20,000  g for 30 minutes. Pelleted material
was sequentially extracted in an equal volume of radio-
immunoprecipitation assay (RIPA) buffer (0.1% SDS,
0.5% deoxycholate, 1.0% Triton X-100, 50 mmol/L Tris
base, 150 mmol/L NaCl, pH 8.0, with PIC) or 2% SDS
(w/v, with PIC) to determine detergent-soluble A, fol-
lowed by 70% (v/v) formic acid (FA) to determine insolu-
ble A.34 In each case, the pellet was extracted by brief
sonication (10 0.5-second microtip pulses at 20% pow-
er; Fisher sonic dismembrator, model 500, Fisher Scien-
tific, Pittsburgh, PA) followed by centrifugation to pellet-
insoluble material (detergent-soluble fraction: 20,000 g
for 30 minutes at 14°C; FA fraction: 20,000  g for 1 hour
at 4°C). Protein content was determined by bicinchoninic
acid assay (Pierce Biotechnology, Rockford, IL).
Immunohistochemical Analysis
For immunofluorescence, sections were labeled for
BACE1 (rabbit monoclonal EPR3956; Epitomics Inc., Bur-
lingame, CA), BACE2 (rabbit polyclonal Ab1; EMD Bio-
sciences, San Diego, CA), glial fibrillary acidic protein
(for astrocytes; clone GA5, MAB360; Millipore, Billerica,
MA), Iba-1 (for microglia; Biocare Medical, Concord, CA),
4G8 (for amyloid deposits; Covance, Denver, PA), orPHF-1 (for pathologic tau; a gift from Dr. Peter Davies,
Albert Einstein College of Medicine, Bronx, NY) (see Sup-
plemental Table S3 at http://ajp.amjpathol.org for a de-
tailed list of all the antibodies used in this study). Sections
were deparaffinized in SafeClear (Fisher Scientific) and
rehydrated before blocking endogenous peroxidase ac-
tivity with 3% hydrogen peroxide in 10% methanol. All the
sections were subjected to antigen retrieval by boiling for
10 minutes in citric acid buffer (10 mmol/L sodium
citrate  0.05% Tween 20, pH 5.0) and blocked (PBS 
2.5% normal goat serum, 2.5% normal donkey serum,
and 0.05% Tween 20). Secondary antibodies were anti-
rabbit Alexa Fluor 568 (red) or anti-mouse Alexa Fluor
488 (green) (Invitrogen, Carlsbad, CA). Slides were
treated with autofluorescence eliminator reagent (Milli-
pore) and coverslipped with Vectashield (Vector Labora-
tories, Burlingame, CA). Alternatively, we used the Vector
avidin-biotin complex kit (Vector Laboratories) with either
3,3=-diaminobenzidine or Vector SG (Vector Laborato-
ries) as substrate.
Enzyme Activity Assays
We recently described and validated the assays for
BACE1 and BACE2 for human tissue in considerable
detail, including reagent specificity.22 This method is sim-
ilar to that of Fukumoto et al.35 Determination of BACE1
(MAB931, raised against the BACE1 ectodomain; R&D
Systems, Minneapolis, MN) or BACE2 (Ab1, raised
against amino acids 496–511 of BACE2; EMD Biosci-
ences) activities was as described.22 In some cases,
validation experiments were performed using two differ-
ent antibodies directed against the opposite ends of
BACE1 (C-terminus, EPR3956; Epitomics Inc.) or BACE2
(N-terminus, rabbit polyclonal Ab2; EMD Biosciences).
For neprilysin (NEP) activity, tissue samples were homog-
enized in 10 volumes of 50 mmol/L potassium phos-
phate buffer, pH 7.3. Samples were centrifuged at 500 
g for 15 minutes at 4°C, and the supernatant was used to
measure NEP activity.36 Specificity was demonstrated by
inhibition with 100 mol/L phosphoramidon or 2 mol/L
CGS24592.37
ELISA
Detergent- and FA-soluble pools of A were measured in
tissue samples using a standard, well-characterized
sandwich enzyme-linked immunosorbent assay
(ELISA).34,38,39 To determine the total amount of A, cap-
ture was performed using monoclonal antibody Ab9
(against the amino-terminus of A), and detection was
performed using biotinylated 4G8 against A17-24 (Cova-
nce), followed by horseradish peroxidase–conjugated
NeutrAvidin (Pierce Biotechnology); A40 was detected
with Ab13.1.1, and A42 was detected with 12F4 (Cova-
nce).38 Alternatively, A42 was captured using Ab2.1.3
and was detected with Ab9; alternative antibody combi-
nations gave essentially identical results. For the mea-
surement of APP or APP CTFs by ELISA, we used a
similar procedure. Antibody 22C11 (Millipore) was used
to capture full-length APP from the sample, which was
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(Covance). The cleared sample was then transferred to a
second plate, coated with affinity-purified antibody CT20,
and raised against the last 20 amino acids of APP (see
Supplemental Figure S2 at http://ajp.amjpathol.org). Cap-
tured CTFs were detected using either antibody 6E10 (for
CTF) or 4G8 (for total CTFs). Oligomeric A was mea-
sured using the single-site 4G8/4G8 sandwich ELISA.34
Real-Time PCR
For RNA isolation, 100 mg of frozen tissue was homoge-
nized using TRIzol reagent (Invitrogen) followed by phe-
nol/chloroform extraction and ethanol precipitation, as
per the manufacturer’s instructions. RNeasy cleanup col-
umns (Qiagen, Valencia, CA) were run for each sample.
The reverse transcriptase reaction (iScript select cDNA
synthesis kit; Bio-Rad Laboratories, Hercules, CA) used 1
g of RNA, purified RNase H, MMLV reverse transcrip-
tase, and a mixture of random hexamers and oligo dT
primer, according to the manufacturer’s instructions.
Primers were designed with the following forward and
reverse sequences, respectively: APP: 5=-AACCAGT-
GACCATCCAGAAC-3= and 5=-ACTTGTCAGGAAC-
GAGAAGG-3=; BACE1: 5=-TATCATGGAGGGCTTCTA-
CGTTG-3= and 5=-GTCCTGAACTCATCGTGCACAT-3=;
BACE2: 5=-GCAACCATGAACTCAGCTATTAAGAA-3=
and 5=-AGAAAGCGCCACCATCGA-3=; and BACE27:
5=-GCCCCAGAAGGTGTTTGAT-3=, 5=-GCTGAATGTA-
AAGCTGAGGC-3=, and 5=-GGCTGAATGTAAAGCA-
GAG-3=. Additional primers were designed for house-
keeping genes with the following forward and reverse
sequences, respectively: tumor protein translationally
controlled 1 (TPT1): 5=-GATCGCGGACGGGTTGT-3= and
5=-TTCAGCGGAGGCATTTCC-3=; glyceraldehyde-3-
phosphate dehydrogenase (GAPDH): 5=-ACCACAGTC-
CATGCCATCAC-3= and 5=-TCCACCACCCTGTTGCT-
GTA-3=; hypoxanthine purine phosphoribosyl-transferase
1 (HPRT): 5=-GACCAGTCAACAGGGGACAT-3= and 5=-
AACACTTCGTGGGGTCCTTTTC-3=; and ribosomal pro-
tein L32 (RPL32): 5=-CATCTCCTTCTCGGCATCA-3= and
5=-AACCCTGTTGTCAATGCCTC-3=.40 Standardization was
performed to the geometric mean of at least two house-
keeping genes. Quantitative real-time PCR reactions
contained 20 ng of sample cDNA together with Per-
feCTa SYBR green supermix (Quanta BioSciences Inc.,
Gaithersburg, MD).
SDS-PAGE and Western Blot Analysis
Proteins were separated using a range of SDS-PAGE
Criterion gels (Bio-Rad Laboratories) and were electri-
cally transferred to 0.45-m nitrocellulose or polyvi-
nylidene difluoride membranes. Primary antibodies used
were rabbit polyclonal CT20, mouse monoclonal MAB931
(BACE1), rabbit monoclonal EPR3956 (BACE1), rabbit
polyclonal Ab1 (BACE2), rabbit polyclonal Ab5670
(BACE2, amino acids 441-457; Abcam Inc., Cambridge,
MA), rabbit polyclonal Ab2 (BACE2), rabbit polyclonal
anti-GAPDH (Abcam Inc.), or mouse monoclonal AC15
(against -actin; Sigma-Aldrich). Horseradish peroxi-dase–conjugated secondary antibodies and enhanced
chemiluminescent detection reagents were obtained
from Pierce Biotechnology.
Data Analyses
Data were analyzed using SPSS (SPSS Inc., Chicago, IL).
Simple group comparisons were made using either Stu-
dent’s t-test or the Mann-Whitney U-test, where appropri-
ate. Group data were analyzed by a general linear model
analysis of variance, covarying for age and postmortem
interval when necessary, and post hoc comparisons were
performed using Dunnett’s test. Correlations were deter-
mined using either Pearson’s r or Spearman’s , where
appropriate.
Results
BACE1 and BACE2 Are Both Present
in Neurons
Using well-characterized antibodies,22 we first examined
the localization patterns of BACE1 and BACE2 in the
human brain (Figure 1). BACE1 and BACE2 immunore-
activity was present in AD and control cases. BACE1-
positive cells were abundant throughout the neocortex
and were often of distinct pyramidal cell morphology.
BACE1 immunoreactivity was mainly present as punctate
perinuclear and cytoplasmic staining, consistent with a
primary localization to the endosomal/lyosomal compart-
ment. We observed numerous BACE2-positive cells that
had the signature stellate appearance of astrocytes, par-
ticularly close to the brain surface. BACE2-positive pyra-
midal neurons were also abundant. These areas fre-
quently contained few BACE1-positive cells. BACE2
immunoreactivity within cells of astrocytic morphology
was more widely dispersed, and the processes were
frequently labeled extensively. We did not observe a
clear relationship between BACE1- or BACE2-positive
cells and deposits of the A peptide in either AD cases or
controls. However, BACE2-positive processes resem-
bling dystrophic neurites were found closely associated
with some plaques. Even in areas where astrocytes were
present in large numbers, we did not observe any that
were clearly BACE1 positive (Figure 2). Although we did
find many examples of BACE2-positive astrocytes, these
were uncommon. We observed BACE2 astrocytic pro-
cesses in association with blood vessels. We did not
observe significant immunostaining for either BACE1 or
BACE2 in microglia (see Supplemental Figure S3 at
http://ajp.amjpathol.org). Hence, although there were
some differences in distribution patterns, both BACE1
and BACE2 were found in neurons.
BACE1 and BACE2 Proteins and Activities
Increase in Neurodegenerative Disease
In an earlier study, we noted that BACE2 was nearly as
abundant in human brain as was BACE1.22 This was also
true in this larger series of cases (Figure 3). We deter-
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standard curves generated from recombinant standards
run on the same Western blot. Although the difference
was not large, the mean  SD amount of BACE1 (4.7 
0.73 ng/g) was higher than that of BACE2 (3.2  0.46
ng/g; t-test, P  0.001; five controls and six AD cases).
The BACE1 isolated from brain migrates near its ex-
pected molecular weight based on the recombinant pro-
tein standard. However, BACE2 migrates at a slightly
lower-than-expected apparent molecular weight. There
are two common splice variants of BACE2 in addition to
the full-length (splice form A) version: BACE2 splice form
B uses an alternative splice site for exon 8 (resulting in a
truncated form with a different C-terminal end), and
splice form C omits exon 7 but is otherwise unchanged
(BACE27). The lower observed relative molecular weight
coupled with the pattern of immunoreactivity (eg, Ab5670
Figure 1. BACE1 (left panels) and BACE2 (right panels) show distinct
patterns of cellular immunoreactivity in the human brain. A and C: BACE1
and BACE2 immunoreactivity was more prevalent in AD brain. Strongly
BACE1-positive cells (brown) of distinct neuronal morphology are found
throughout the neocortex and are not clearly associated with A deposits
(blue); this was true for AD and control cases. B and D: BACE2 immunore-
activity (brown) was also found in neurons, but rare BACE2-positive pro-
cesses were observed intertwined with plaques (blue). E and G: Many
BACE2-positive cells with a distinctive astrocytic morphology are clustered in
the outer cortical layer, in areas largely devoid of BACE1-positive cells. F and
H: Although some BACE1 is found in cellular processes, most BACE1 immu-
noreactivity is localized in a punctate perinuclear pattern; in contrast, BACE2
has a broader distribution that may fill the entire cell (counterstain: cresyl
violet). Antibodies: BACE1, mouse monoclonal MAB931; BACE2, rabbit poly-
clonal Ab2; and A, mouse monoclonal 4G8. Substrates: 3,3=-diaminobenzi-
dine (brown) or Vector SG (blue).will not detect BACE2 splice form B) indicates that themajor form of BACE2 protein in the human brain is likely
splice form C.
Overall, BACE1 (F4,32  2.89, P  0.04) and BACE2
(F4,32  2.87, P  0.04) activities were increased in
neurodegenerative disease (Figure 4). The increase oc-
curred in a disease-affected region [the superior and
middle temporal gyri (SMTG), areas 21 and 22] but not in
a brain region unaffected by disease [the cerebellum
(CB)]. Although enzymatic activity was not increased in
the CB with disease, BACE1 (R2  0.25, P  0.001) and
BACE2 (R2 0.08, P 0.04) activities in the CB were still
significantly correlated with activities in the SMTG. The
same increases in a disease-affected region (SMTG) but
not in an unaffected region (CB) were seen for BACE1
(F4,32  5.87, P  0.001) and BACE2 (F4,32  15.03, P 
0.0001) proteins using Western blot analysis (Figure 3),
when examined by densitometry. The results were un-
changed when the data were not standardized to -actin
as a loading control. The results were also the same when
Figure 2. BACE2 was observed in neurons and astrocytes. Most BACE2
immunoreactivity was found in the cortical layer near the surface of the brain
and in areas surrounding blood vessels. A: BACE1 was not seen in astrocytes,
even in areas where substantial numbers of astrocytes were clearly labeled or
in areas of extensive gliosis. B: BACE2-positive astrocytes were rarely found
(arrowhead) in areas of extensive neurodegeneration and gliosis. C and D:
BACE1 and BACE2 were present in neocortical pyramidal neurons. E and F:
BACE1- and BACE2-negative astrocytes in close proximity to positive-labeled
cells, some of which are distinctively neuronal in morphology. G: A BACE2-
positive astrocyte (yellow arrow) showing strong cytoplasmic labeling. H
and I: BACE2-positive astrocytic processes (white arrow) are often found in
association with blood vessels. Antibodies: BACE1, rabbit monoclonal
EPR3956 (red); BACE2, rabbit polyclonal Ab2 (red); and glial fibrillary acidic
protein, mouse monoclonal MAB360 (green). Counterstain: DAPI (blue).
Scale bars: 25 m.
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group (the amount of pathologic disease in these cases
is nearly identical; Supplemental Table S1 and Supple-
mental Figures S1 and S4 at http://ajp.amjpathol.org). As
expected from earlier assay validation studies, BACE1
and BACE2 activities were correlated with their respec-
tive protein bands detected by immunoblot analysis
(BACE1: R2  0.17, P  0.006; BACE2: R2  0.21, P 
0.002). Also, consistent with a general increase in
-secretase activity, the APP CTF/CTF ratio was higher
in AD in the SMTG (F4,34 6.15, P 0.001) but not in the
CB, as determined by immunoblot analysis (see Supple-
Figure 3. BACE1 (A) and BACE2 (B) are abundant in human brain. Equal
amounts of protein from the SMTG (25 g) were separated by SDS-PAGE
under reducing conditions on Criterion 10% to 20% Tris-glycine gels (Bio-Rad
Laboratories). Controls included human recombinant BACE1 (100 ng; R&D
Systems) or mouse recombinant BACE2 (100 ng; R&D Systems) and cell
lysate from H4 neuroglioma cells (25 g; these cells contain relatively little
BACE1 but have readily detectable BACE2). Samples were transferred to
0.45-mol/L nitrocellulose membranes and blocked overnight. After probing
for BACE1 (MAB931) or BACE2 (Ab5670), blots were stripped and reprobed
for -actin. Although -actin was broadly similar, in some cases the levels
were very low. Comparison with recombinant protein standards indicates
similar quantities of BACE1 and BACE2 protein, although there is slightly
more BACE1 (see Results). Although the BACE1 band migrates close to the
recombinant protein standard, BACE2 runs at a slightly lower apparent
molecular weight. The lower-than-expected molecular weight of this band
and the observed pattern of antibody immunoreactivity together indicate that
the active form of BACE2 in the brain is likely BACE27 (splice form C).mental Figure S5 at http://ajp.amjpathol.org). The CTF/CTF ratio was also modestly correlated with BACE1 (R2
0.07, P  0.05) and BACE2 (R2  0.07, P  0.05) activity.
The outcome was similar when the SMTG ratio was stan-
dardized to the CTF/CTF ratio in the CB, and the overall
disease effect was significant (F4,34  4.97, P  0.01).
These data indicate that an increase in BACE1 and BACE2
activities and protein levels likely occurs at an early disease
stage.
We observed a striking correlation between BACE1
and BACE2 in human brain, a phenomenon observed
with multiple antibody combinations and assay condi-
tions. Using a standard assay for BACE1 (MAB931) and
BACE2 (Ab1) activities, we found strong correlations be-
tween the two enzymatic activities in the SMTG (R2 0.9,
P  0.0001) and the CB (R2  0.7, P  0.001), indicating
that this was unrelated to disease. To confirm this finding,
we repeated the assay using a different method. In the
validation test, we reversed the orientation of the assay
and used different antibodies, capturing BACE1 at the
C-terminus (using EPR3956) and BACE2 at the N-termi-
nus (using Ab2). BACE1 and BACE2 activities remained
highly correlated in the SMTG (R2 0.64, P 0.001) and
the CB (R2  0.47, P  0.001) (Figure 4). We observed
similar disease-related increases in BACE1 and BACE2
using this alternate method (see Supplemental Figure S6
Figure 4. BACE1 and BACE2 are increased in neurodegenerative disease. A:
BACE1 activity (as determined by the MAB931 capture assay) is higher in
PCAD, AD, and FTD. B: BACE2 activity (as determined by the Ab1 capture
assay) is higher in FTD and PCAD and strongly trends toward an increase in
AD (P 0.07). C: BACE1 protein is higher using Western blot analysis in FTD
and AD (Figure 3). D: BACE2 protein is higher using Western blot analysis in
MCI, PCAD, AD, and FTD (Figure 3). Immunoblot analysis results were
essentially unchanged when not standardized to -actin, indicating that
outlier cases with very low -actin levels had minimal effect on the analysis.
E and F: BACE1 and BACE2 activities are highly correlated, a phenomenon
observed with multiple antibodies and assay conditions (shown: BACE1,
EPR3956 capture assay; BACE2, Ab2 capture assay). Dunnett’s test, *P 
†0.05, P  0.01. Scale: 1000 base fluorescence units (BFU)/mg  2.3
nmol · min1 · mg1 total protein.
determi
tein.
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BACE1 (using MAB931) and BACE2 (using Ab5670) re-
lationship by immunoblot analysis and detected a simi-
larly strong correlation (R2  0.32, P  0.001). The cor-
relation was significant regardless of whether the data
were standardized to -actin. Hence, we detected strong
correlations between BACE1 and BACE2 proteins and
activities using different methods.
We next wanted to determine whether changes in the
-secretase enzymes occurred only at the level of protein
and activity or extended down to the mRNA level. The
total amount of BACE1 or BACE2 mRNA did not change
with disease state (see Supplemental Figure S7 at http://
ajp.amjpathol.org). The amounts of BACE1 and BACE2
mRNA correlated with each other in the SMTG (R2 0.48,
P  0.001) and the CB (R2  0.72, P  0.001), but in
neither case did the amount of total mRNA correlate with
the amount of BACE1 or BACE2 activity or protein. Be-
cause immunoblot data indicated that the form of BACE2
in the brain might be missing exon 7, we developed an
assay to specifically detect this form. Although the total
BACE2 mRNA level did not change with disease state,
the BACE27 mRNA level increased (F4,28  3.07, P 
0.04) in a pattern similar to that seen for protein and
activity (Figure 5A). Increases in the amount of BACE27
mRNA were positively correlated with BACE2 enzymatic
activity (R2 0.38, P 0.001; Figure 5B) and the amount
of BACE2 protein detected by Western blot analysis
(R2  0.31, P  0.001; Figure 5C). BACE2 enzymatic
activity and BACE2 protein by Western blot analysis were
determined using antibodies directed against different
regions of the BACE2 protein, both of which do not detect
BACE2 splice form B (the other shorter form of BACE2).
Together, these data suggest that the principal active
isoform of BACE2 in the human brain lacks exon 7 and
increases in neurodegenerative disease.
BACE1 and BACE2 Proteins and Activities Are
Unchanged in DS
Because we detected a substantial amount of both forms
Figure 5. The mRNA for the splice form of BACE2 missing exon 7 (splice fo
expression increased with disease state (P  0.04) and was significantly elev
RPL32, GAPDH, and HPRT (total mRNA did not change). The increase in
determined by Ab1 capture assay) (B) and the amount of BACE2 protein (as
1000 base fluorescence units (BFU)/mg  2.3 nmol · min1 · mg1 total proof -secretase in the brain, we were interested in howeach might be connected to AD-related neuropathology
and to the amount of the A peptide. We reasoned that
these questions might be examined in detail by studying
postmortem brain specimens from individuals with DS,
who possess an additional copy of the APP and BACE2
genes. As individuals with DS age, they develop substan-
tial A deposition, along with other aspects of AD pathol-
ogy.41 This may be related to the overexpression of APP,
BACE2, or both because the genes for both proteins
reside in the DS obligate region of chromosome 21.
As expected, total mRNA levels for BACE2 (Mann-
Whitney U-test, P  0.01) and APP (P  0.05) were
increased in DS brains versus controls (Figure 6A). The
total mRNA level for BACE1 was unchanged in DS cases
(data not shown). We detected a small increase in the
amount of APP protein (P 0.05) but not in the amount of
BACE2 protein. Expression of full-length APP protein did
BACE7) is increased in neurodegenerative disease. A: The BACE27 mRNA
late-stage AD and FTD; values were standardized to the geometric mean of
7 mRNA was positively correlated (P  0.001) with enzymatic activity (as
ned by Ab5670 immunoblot) (C) (Figure 4). Dunnett’s test, *P  0.05. Scale:
Figure 6. BACE1 and BACE2 enzymatic activities and protein levels are not
increased in DS. A: As expected, total mRNA levels for BACE2 and APP were
significantly higher in DS cases; BACE1 mRNA was unchanged (data not
shown). DS cases had slightly more APP protein but no additional BACE2
protein. B: BACE1 and BACE2 enzymatic activities were unchanged between
DS cases and controls. C: Neither BACE1 (MAB931) nor BACE2 (Ab5670)
protein levels differed between DS cases (mean  SD: BACE1, 89.9  19.7;
BACE2, 218.9 10.5) and controls (mean SD: BACE1, 89.8 21.4; BACE2,
222.3 6.5) (arbitrary units). D: BACE1 showed a slight age-related decrease
†rm C, or
ated in
BACE2in activity. Mann-Whitney U-test, *P  0.05, P  0.01. Scale: 1000 base
fluorescence units (BFU)/mg  2.3 nmol · min1 · mg1 total protein.
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which may partially account for why the overall APP
increase in DS was relatively small across the entire pool
of subjects. BACE1 (F1,34  0.96, P  0.34) and BACE2
(F1,34  1.14, P  0.30) enzymatic activities (Figure 6B)
and protein levels (Figure 6C; also see Supplemental
Figure S8 at http://ajp.amjpathol.org) were not different
between DS cases and the series of age-matched control
cases. Power calculations (  2.80) indicated that we
are able to detect a difference of 19% between the two
groups with this number of subjects. Because the mRNA
for BACE2 is increased approximately twofold in DS, this
leads us to conclude that the additional message is not
efficiently translated into protein. Similarly, using immu-
noblot analysis, we did not see differences between
CTF that might correspond to differences in -secretase
activity in DS. We also examined CTF standardized to
APP by ELISA and also did not detect any change that
might correspond to altered -secretase activity (see
Supplemental Figure S9 at http://ajp.amjpathol.org).
BACE1 activity decreased a small amount with age
across DS and control cases (Figure 6D; P  0.01). As
with the previous set of neurodegenerative disease–af-
fected cases, the activities of BACE1 and BACE2 were
highly correlated (R2  0.9, P  0.0001).
BACE1 and BACE2 Activities Are Related to
Soluble but Not Insoluble A in the Brain
Because individuals with DS have an extra copy of APP
and BACE2, they represent a unique population in which
to evaluate the interactions between -secretase expres-
sion and the deposition of A in the brain. The amount of
A in all fractions analyzed was substantially higher in DS
cases (Figure 7A; F4,31  16.14, P  0.001) compared
Figure 7. A increases with age in DS but is not related to -secretase
activity. A: The overall amount of A was higher in DS in all fractions (P 
0.01). Shown: total A extracted in either RIPA buffer (F1,34  14.14, P 
0.001) or 70% FA (F1,34 40.09, P 0.0001). B: The amount of A increased
with age in DS cases (P  0.001) and matched controls (P  0.05). Neither
BACE1 (C) nor BACE2 (D) enzymatic activities were related to the amount of
either RIPA (not shown) or FA-soluble A in the brain. Scale: 1 base fluo-
rescence unit (BFU)/g  2.3 nmol · min1 · mg1 total protein.with controls, and the amount of A increased substan-tially with age (Figure 7B; F4,31  4.13, P  0.01). There
was no relationship between the amount of either RIPA
(not shown) or FA-soluble A and BACE1 (Figure 7C) or
BACE2 (Figure 7D) activities. The results did not change
when the analysis was restricted to only A42, to DS
cases alone, or to control cases alone. These data were
somewhat surprising given recent studies suggesting
that a positive feedback mechanism may exist in which
A drives the up-regulation of BACE1 expression.42,43
We decided to explore this relationship in greater de-
tail by revisiting the cases from our first group, in which
we had access to more detailed neuropathologic data.
Neither BACE1 nor BACE2 activity could predict the num-
ber of diffuse plaques or neuritic plaques (NPs) (data not
shown). BACE1 (R2  0.12, P  0.03) and BACE2 (R2 
0.13, P  0.03) activities were significantly positively re-
lated to the amount of A in the NaOAc-soluble fraction
isolated from the SMTG in this case series. Although
these relationships were modest (Figure 8, A and B), we
found similar results in the CB in these same cases
(BACE1: R2  0.10, P  0.03; BACE2: R2  0.09, P 
0.03; data not shown). The NaOAc fraction is the first in
the extraction series, contains the most soluble pool of A
peptides, and is also where BACE1 activity is localized.22
There was no relationship between either BACE1 or
BACE2 enzymatic activities and any form of A (total A,
A40, A42, or oligomeric A) extracted in the RIPA,
SDS, or FA fractions (Figure 8, C and D). The amount of
CTF in SMTG was related to the amount of A in multiple
fractions (R2  0.22 to 0.15, P  0.05) and was also
related to the number of NPs (R2  0.22, P  0.002); this
stronger relationship is likely due to CTF being the im-
mediate precursor to A, whereas -secretase activity is
a step further removed.
Examining BACE1 and BACE2 using methods other
than enzymatic activity produced largely the same re-
sults, with some important differences. First, the amount
Figure 8. BACE1 and BACE2 enzymatic activities are related to soluble, but
not insoluble, A in the brain. BACE1 (A) and BACE2 (B) enzymatic activities
were significantly correlated with the amount of A solubilized in the NaOAc
fraction, which contains the most soluble pool of the peptide. Neither BACE1
(C) nor BACE2 (D) enzymatic activities were correlated with less-soluble
forms of A, such as the pool soluble in 70% FA. Scale: 1000 base fluores-
cence units (BFU)/mg  2.3 nmol · min1 · mg1 total protein.
amount
ot show
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correlated with the number of NPs (R2  0.14, P  0.02)
but not with the number of diffuse plaques (R2  0.03,
P  0.3). Also, the number of NFTs was positively corre-
lated with BACE2 protein (R2  0.16, P  0.01) and
mRNA (R2  0.15, P  0.02). The relationship between
BACE2, NFTs, and NPs may be connected to BACE2-
positive neurites (Figure 1). However, we did not detect
any strong cellular co-localization between BACE2-posi-
tive cells and pathologic forms of the microtubule-binding
tau protein (see Supplemental Figure S10 at http://ajp.
amjpathol.org). This finding suggests that although
BACE2 may increase in parallel with tangle pathology,
this may be occurring in general in broad areas of neu-
rodegeneration rather than in specific cells. Finally, the
amounts of BACE1 (R2  0.10, P  0.05) and BACE2 (R2
 0.16, P  0.01) proteins showed a slight positive cor-
relation with the amount of SDS-extractable A. It is pos-
sible that this may partially account for discrepancies
between the present data and other published results.
Insoluble A in the Brain Is Accounted for by
Decreased NEP Activity
The activities of neither BACE1 nor BACE2 significantly
accounted for the least-soluble forms of A in the brain.
The amount of A in the brain at the time of death, and the
number of amyloid deposits, reflects the steady-state
level of the peptide. Because -secretase is the rate-
limiting enzymatic activity in the production of A, and
because neither form of -secretase can explain most of
the A peptide in the brain at the time of autopsy, we
reasoned that the process of A catabolism would likely
account for the remaining insoluble peptide. We tested
this hypothesis by evaluating the activity of NEP, one of
the major A clearance enzymes in the brain.44
NEP activity decreased in the SMTG in neurodegen-
erative disease (F4,30  2.72, P  0.05; Figure 9A). This
effect was driven primarily by lower NEP activity in AD
(Dunnett’s test, P  0.005), although PCAD cases were
also significantly reduced (P  0.04). In the CB, NEP
Figure 9. NEP enzymatic activity decreases in neurodegenerative disease
increased in an unaffected region (CB; P  0.01); these effects were mostl
correlated (P  0.05) with the pool of least-soluble A peptide in the brai
(P  0.01) with the number of NPs in the brain; the number of NPs and the
0.0001). NEP was not correlated with the number of diffuse plaques (data nactivity was significantly higher in disease (F4,27  4.87,P 0.005), and this increase was prominent in late-stage
AD cases (P  0.05). NEP activity showed a significant
negative correlation with the total amount of A in the
brain, as determined by two independent replications
(R2  0.14, P  0.02; R2  0.13, P  0.03). A stepwise
multiple regression analysis revealed that the variance in
NEP activity is explained by a model combining SDS- and
FA-soluble A (R2  0.22; F2,35  5.00, P  0.02),
whereas BACE1 (R2  0.13; F1,39  5.67, P  0.03) and
BACE2 (R2  0.14; F1,39  6.31, P  0.02) are signifi-
cantly related only to the amount of A soluble in NaOAc
(Figure 8). The FA-soluble A42 pool accounted for the
greatest proportion of the variance in NEP in the SMTG
(R2  0.11, P  0.03; Figure 9B). NEP activity was not
related to BACE1 or BACE2 enzymatic activity, oligo-
meric A, or the number of diffuse plaques. However,
NEP activity showed a significant negative correlation
with the number of NPs (R2  0.15, P  0.01; Figure 9C).
Due to constraints on tissue availability, analysis was
limited on the DS cases. Using the same method as in the
first case series, we again observed that NEP activity was
inversely related to the amount of A42 in the least-
soluble fraction, FA (R2  0.28, P  0.03; see Supple-
mental Figure S11 at http://ajp.amjpathol.org). Together,
these data are consistent with decreased NEP activity
accounting for the increased quantity of insoluble A
deposits in the diseased brain.
Discussion
The key involvement of -secretase in AD is now well-
established. Until recently, most research in this area
focused on furthering our understanding of BACE1. This
emphasis has been driven by the results of several stud-
ies in genetically modified mice indicating that most of
the A peptide in the brain is produced by BACE115,19,20
but also by other studies showing that BACE2 is less
prominent in the brain.11 In this study, we demonstrate for
the first time that disease-related increases in BACE1 are
accompanied by corresponding increases in BACE2,
that both increase at an early disease stage, and that
activity is decreased in a disease-affected region (SMTG; P  0.05) and
by large differences in late-stage AD cases. B: NEP activity was inversely
tractable A42. C: NEP activity was significantly and negatively correlated
of FA-soluble A42 are strongly correlated with each other (R2  0.61, P 
n). Dunnett’s test, *P  0.05, †P  0.01.. A: NEP
y driven
n, FA-exthese increases are not necessarily specific to AD or
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creases do not necessarily accompany aging or deposition
of the A peptide in the brain. Finally, only the more soluble
pool of A is related to -secretase activity, with the quantity
of the least-soluble peptide being better accounted for by
the activity of catabolic enzymes, such as NEP.
The amount of BACE2 and BACE1 protein and activity
increased early in the progression of AD, before the onset
of dementia. This finding indicates that increasing
-secretase activity is an early feature of the disease and
may play a causal role in the development of neuropa-
thology. Higher levels of -secretase activity have been
reported in disease-affected brain regions in late-stage
AD,21,22,24,25 although these studies have focused
largely on BACE1. Furthermore, although there have
been earlier reports of modest increases in BACE1 pro-
tein or -secretase activity in cerebrospinal fluid 27 and
platelets28 from amnestic MCI cases, this is the first re-
port describing a detailed examination in brain tissue
from early-stage disease. Two earlier studies attempted
to separate BACE2 and BACE1 in the AD brain; one
observed no change22 and the other reported a small
decrease45 in the amount of BACE2 protein. However,
both of these studies used 16 or fewer cases and com-
pared only late-stage AD cases with controls. It is also
possible that discrepancies between these two studies
and the present study may arise from the study of differ-
ent tissue brain regions or that these other studies used
tissue specimens with longer postmortem intervals.
Stockley et al45 evaluated only BACE2 by immunoblot
analysis but saw a small decrease in a prominent band at
75 kDa. It is possible that this BACE2 band may repre-
sent a stable dimer of what we report herein as the active
form because BACE1 is thought to exist as a functional
dimer.46 It is also possible that disease-related differ-
ences may alter the proportion of BACE2 in a monomeric
versus dimeric state.
In contrast to the increases in BACE1 and BACE2 in
neurologic disease, we did not see an increase in either
form of -secretase in DS. Despite the additional copy of
the BACE2 gene, the BACE2 protein is not thought to be
overexpressed in DS.47–49 A possible relationship be-
tween BACE2 and other AD-like neuropathologic features
(such as NFTs) in older DS cases was reported,14 but this
has not been extensively studied. Other researchers
have reported that BACE1 and BACE2 are comparable in
DS brain47 and that overall -secretase activity in DS
brain is similar to that in normal individuals over the same
range of ages.50 It would, thus, seem that increases in
-secretase activity, either BACE1 or BACE2, are not a
feature of DS. However, individuals with DS have dys-
functions in the endosomal/lysosomal system that de-
pend on APP and BACE1, but not on A, overexpres-
sion.51 This finding implies that the CTF generated as a
consequence of -secretase activity may be directly in-
volved in DS neuropathology at a different level.
We did not observe disease-related increases in the
total amount of mRNA for either BACE2 or BACE1.
Although several studies indicate that BACE1 protein
and activity increase in the absence of changes in
mRNA,24,43,52 the issue has not been completely re-solved.21,53 As an important positive control, we detected
more total mRNA for BACE2 and APP in the brains of
patients with DS but no increase in the total amount of
BACE1 mRNA, findings similar to others.48,49,51 Although
we saw no change in the total amount of mRNA, we
detected an increase in mRNA for BACE27 (splice form
C) that approximately corresponded to BACE2 protein
and activity. Although it is beyond the scope of this study,
this finding raises the issue that at least some of the
discrepancies in BACE1 data between other studies may
relate to the primer or probe sets used because only one
or more splice forms may actually change in the diseased
brain. BACE1 activity, but not mRNA, has been reported
to increase in Tg2576 mice with age,54 although there is
a tendency toward an increase in the mRNA of a more
active splice variant (I-501). The relationship between this
splice form of BACE1 and -secretase activity in the AD
brain has not been examined in great detail, other than a
report of its regional distribution.8 Disease-related
changes may not be uniform between affected brain re-
gions, and additional confusion may derive from the lack
of good reference genes that are stable across disease
states.53
Although we detected strong, reproducible increases
in both forms of -secretase in early- and late-stage AD,
this increase was not necessarily specific to AD. In FTD,
we observed increases in BACE1 and BACE2 that were
of approximately the same magnitude as what we saw in
late-stage AD. This finding indicates that perhaps neuro-
degeneration in general leads to up-regulation of
-secretase expression. This could correspond to other
known functions of BACE1, such as its reported role in
myelination,5 because BACE1 might be expected to be
up-regulated during repair processes triggered in dam-
aged regions.6 The observed increase in BACE2 could
be related to its expression in astrocytes, which express
essentially no BACE1 at the protein level.55 However, we
did not observe increases in either form of BACE in DS
cases, even in older cases with AD-related neuropathol-
ogy. Older individuals with DS show substantial evidence
of white and gray matter degeneration and loss of brain
weight.56 It would, thus, seem that the increase in
-secretase cannot be broadly attributed to neurodegen-
eration in general. A detailed study documenting the
differences among AD, FTD, and DS may help elucidate
the underlying elements directly responsible for control-
ling BACE1 and BACE2 expression.
We found a striking relationship between BACE1 and
BACE2 in the human brain: both forms of -secretase
were highly and reproducibly correlated with each other.
We observed this relationship using multiple methods
(RT-PCR, immunoblot analysis, and enzymatic activity
assays), with different antibodies directed against differ-
ent portions of the proteins, in different brain regions
(middle frontal gyrus, SMTG, and CB), and in autopsy
specimens obtained from different sources comprising
brains of varying ages and neurologic statuses. The par-
simonious explanation for this finding is that BACE1 and
BACE2 must, to a large extent, share their mechanisms of
regulation. BACE1 transcription is regulated by STAT3,57which can be controlled by cyclin-dependent kinase 5
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kinase 1 or c-Jun N-terminal kinase pathways.58 The
BACE1 5= untranslated region is a strong suppressor of
translation59 and is probably a major site of the posttran-
scriptional control of BACE1 expression.43 However, sev-
eral microRNA species are involved in the posttranscrip-
tional regulation of BACE1 through its 3= untranslated
region,60,61 and BACE1 expression may be regulated
globally by its naturally occurring antisense transcript.62
Considerably less is known about the factors that regu-
late BACE2 expression. However, the major shared tran-
scription factor between the BACE1 and BACE2 promot-
ers is Sp1.63 This point suggests that at least one
component of the relationship we observed may be
driven by shared changes in this transcription factor.
Changes in Sp1 levels track with the amount of BACE1
mRNA,64 and Sp1 dysregulation occurs in AD65; it is
unclear whether this relationship is direct. The BACE1
and BACE2 promoters also share several additional tran-
scription factors, including AP1, AP2, and GATA1,12,63,66
and it is conceivable that these may be more important
for the connection between the two. For example, the AP2
site may be important for BACE1 expression in neu-
rons.67 Because BACE1 transcription is likely controlled
from a single nexus, whereas BACE2 is controlled from at
least two,67 this would also make AP2 a good candidate
for a shared regulator. Regardless, because BACE1 is
absent from glial cells55 and BACE2 is found in neurons
and glia,9 the major point of overlap between the two
enzymes is likely in neurons. If there are cell-specific
mechanisms that control -secretase expression at mul-
tiple levels, some of these may be either normally absent
in neurons or lost during the course of disease.
We detected a significant correlation between the
most-soluble pool of A and -secretase enzymatic ac-
tivity but not with the least-soluble A pool. It is the
least-soluble pool of A that shows the strongest corre-
lations with the number of plaques in the brain, and these
were also poorly correlated with -secretase activity. This
finding is consistent with the more-soluble A being
the most recently generated, dynamic pool (and, there-
fore, more likely to correlate with -secretase activity),
whereas the insoluble pool reflects A accumulated over
an extended period and, therefore, subject to many other
factors. Furthermore, although there were substantial
amounts of total A in the brains of older DS cases, there
were no associated increases in either BACE1 or BACE2.
This finding indicated that age-related A deposition in
DS is likely driven more by an overabundance of APP
substrate than by increased -secretase. We also ob-
served large increases in BACE1 and BACE2 protein and
activity in the brains of individuals with FTD, although the
amount of deposited A was negligible in these cases.
The FTD cases were significantly younger than the other
cases, and it is possible that had these individuals lived
longer they would have developed some amyloid depo-
sition. However, this seems unlikely because A deposi-
tion is not considered a feature of FTD neuropathology.
These data suggest that it is also unlikely that there is a
simple positive feedback mechanism in which A depo-
sition drives -secretase expression, as has been sug-gested.21,25,42,43 BACE1 or -secretase activity has also
been shown not to correlate with A-related pathologic
findings in the brain or to be a weak association.35 It is
possible that under some circumstances the relationship
may be less clear, such as with forms of truncated or
modified A that may be missed or underestimated by
certain extraction methods or immunoassays.68 Zhao
et al42 noted that the increase in BACE1 immunoreactivity
occurred only around a subset of plaques in the AD
brain. We detected a relationship between BACE1 and
BACE2, as determined by immunoblot analysis, and the
amount of less-soluble A and between BACE2 and NPs.
Taken together, although it would seem that there is a
relationship between A, BACE1, and BACE2 in the hu-
man brain, this is not as robust as other disease-related
changes.
Although there is a substantial amount of A in the
brain of an individual with AD, the final amount represents
the balance between its production, deposition, and
clearance. For instance, the overall rate of clearance of
A from the brain is impaired in AD, but its production is
not.69 In light of the weaker-than-expected relationship
between -secretase activity and A, we investigated the
relative relationship between NEP activity and neuro-
pathologic features in these same cases. NEP and insu-
lin-degrading enzyme account for most A degradation
in the brain,44,70 and the activity of both decreases in
normal aging and in disease-affected regions.71,72 NEP,
but not insulin-degrading enzyme, is also negatively cor-
related with the amount of A in the brains of AD cases,
suggesting that it is actually the major enzyme responsi-
ble for A catabolism in the brain.73 NEP activity may also
decrease in cerebrospinal fluid in the early stages of
AD.74 Consistent with these observations, we found that
the reduced NEP activity better accounted for the amount
of insoluble A in the brain (including the number of NPs)
than did either BACE1 or BACE2 activity. In areas not
prone to A deposition, including the periphery, NEP
expression was much greater than in AD-vulnerable brain
regions.52 In fact, we observed a significant increase in
NEP activity in the CB of AD cases, possibly explaining
the relative lack of neuropathologic findings in this region
despite significant -secretase activity and substantial
quantities of A. Note, however, that NEP is largely a
synaptic protein, and, therefore, decreases observed in
disease-affected regions may reflect significant synaptic
loss. In recent studies by Miners et al, NEP activity in-
creased in AD75 and DS76 cases when approximately stan-
dardized to neuron number, suggesting that further study is
needed in other disease states and brain regions.
Although significant effort has been invested to further
our understanding of the role of BACE1 in AD, little atten-
tion has been given to the closely related BACE2. This
emphasis should be reevaluated for several reasons.
First, both forms of -secretase cleave APP at the normal
-site (M1-D1) and at internal positions in the A peptide
sequence: Y10-E11 for BACE1 and F19-F20-A21 for
BACE2. Thus, although the preferences are slightly dif-
ferent, BACE2 can generate cleavage products similar to
BACE1, including the full-length A peptide.9,11,20,63Second, because both forms of BACE compete for the
348 Holler et al
AJP January 2012, Vol. 180, No. 1same substrate pool,10 even small changes in BACE2 in
the human brain may indirectly contribute to the devel-
opment of AD simply by altering the available substrate
pool for BACE1. Third, although BACE1 knockout sub-
stantially reduces the amount of A in the mouse brain,20
there is residual A production (likely glial) that can be
attributed to BACE2. Because the population of glia is an
order of magnitude greater than the population of neu-
rons in the brain, this could be a significant disease
mechanism. Finally, the finding that the overexpression of
BACE2 in the mouse brain does not necessarily increase
A77 does not rule out a role for this form of the enzyme
in the human disease because the overexpression of
BACE1 often gives ambiguous results.78,79 The present
findings indicate that in human brain, the expressions of
both forms of -secretase are tightly linked and may play
a combined role in neurologic disease. A better under-
standing of the normal function of BACE1 and BACE2,
and how this function changes in different disease states,
is essential for future therapeutic development.
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